PTGS2 and neoplasm: In the ER-positive MCF7/HER2-18 treated tumours, the percentage of residual COX-2 expression significantly correlated with tumour growth, but in the ER-negative MDAMB231-treated tumours, there was no correlation between residual COX-2 expression and growth.